

The design and statistical analysis of experiments involving laboratory animals

Michael FW Festing, Ph.D.,
D.Sc., CStat.

michaelfesting@aol.com

www.3Rs-reduction.co.uk

A PPL course




Michael FW Festing, Ph.D., D.Sc, Cstat

1966-1981 Geneticist, MRC Laboratory animals centre



Aim of the LAC: To supply high quality, disease-free breeding stock to research workers and commercial breeders.



Some personal research: Mandible shape for genetic quality control c1970s






FIGURE 2 Canonical variate analysis of inbred strains of rats; 1st and 2nd canonical variates. Each point represents mean of a sample of between 8 and 30 rats. Two colonies, one LH and PVG (encircled), were poor fits against their group means (see text). Four samples of LEW/SeN rats were obtained from a colony held at the Laboratory Animals Centre in 1978/79 and prepared in a similar manner. (Samples of the other inbred strains maintained at the LAC sampled in 1977/79 fitted well.)




Fig. 1 Distribution of the within-sample phenotypic standard deviation of an index of mandible shape in F_2 hybrid, outbred (O), inbred (I) and F_1 hybrid mice. Arrows indicate the mean, n is the number of samples. Sample size averaged 12 mice.

Some personal research: Strain differences in escape time in a water maze




Fig. 1. Strain means for experiment 1.




Fig. 2. Learning curves averaged across strains.

Some personal research: Exercise in a running wheel




Fig. 3. Genetic and age differences in wheel running by mice. Each point represents the mean number of revolutions of 2 mice over a 5-day period.

The design and statistical analysis of experiments involving laboratory animals



Principles of Humane Experimental Technique Russell and Burch 1959


- ❑ Replacement
 - ❑ e.g. in-vitro methods, less sentient animals
- ❑ Refinement
 - ❑ e.g. anaesthesia and analgesia, environmental enrichment

- ❑ Reduction
 - ❑ Research strategy
 - ❑ Shotgun vs Fundamental
 - ❑ Controlling variability
 - ❑ Genetics, appropriate model
 - ❑ (disease)
 - ❑ Experimental design and statistics



FRAME

Concern about the quality of animal research expressed in 1992



Outlined the principles of good experimental design and did a small survey of published papers (mostly toxicology)

1. Few used randomised block designs even though this is the most common design in agricultural and industrial research.
2. Factorial designs rare although they provide extra information at no extra cost

Festing, M. F. W. "The scope for improving the design of laboratory animal experiments." Laboratory Animals 26 (1992): 256-67.

Won first prize in a GV-SOLAS competition for the best published or unpublished paper on laboratory animal science

Concern about the quality of animal research



A meta-analysis of 44 randomised controlled animal studies of fluid resuscitation

- Only 2 said how animals had been allocated
- None had sufficient power to detect reliably a halving in risk of death
- Substantial scope for bias
- Substantial heterogeneity in results, due to method of inducing the bleeding
- Odds ratios impossible to interpret
- Authors queried whether these animal experiments made any contribution to human medicine


Roberts et al 2002, BMJ 324:474

Six meta-analyses showing poor agreement between animal and human responses, 2007




Intervention	Human results	Animal results (meta-analysis)	Agree?
Corticosteroids for head injury	No improvement	Improved neurological outcome n=17	No
Antofibrinolytics for surgery	Reduces blood loss	Too little good quality data n=8	No
Thrombolysis with TPA for acute ischaemic stroke	Reduces death	Reduces death but publication bias and overstatement (n=113)	Yes
Tirilazad for stroke	Increases risk of death	Reduced infarct volume and improved behavioural score n=18	No
Corticosteroids for premature birth	Reduces mortality	Reduces mortality n=56	Yes
Bisphosphonates for osteoporosis	Increase bone density	Increase bone density n=16	Yes

Funnel plots and publication bias



Each dot is one experiment.
Small negatives have remained unpublished.



Large powerful studies

small negative studies

small positive studies

Funnel plot demonstrating possible but not statistically significant publication bias in assessment of pain ($P > 0.05$). -Dashed diagonal lines indicate 95% CI

[J Ther Ultrasound](#). 2017 Apr 1;5:9. doi: 10.1186/s40349-017-0080-4. eCollection 2017.

A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound.

[Dababou S](#)¹, [Marrocchio C](#)¹, [Rosenberg J](#)², [Bitton R](#)², [Pauly KB](#)², [Napoli A](#)³, [Hwang JH](#)⁴, [Ghanouni P](#)².

Problems with published papers



Survey of a random sample of 271 published papers using laboratory animals

Of the papers studied:

- 87% did not report random allocation of subjects to treatments
- 86% did not report “blinding” where it seemed to be appropriate
- 100% failed to justify the sample sizes used
- 5% did not clearly state the purpose of the study
- 6% did not indicate how many separate experiments were done
- 13% did not identify the experimental unit
- 26% failed to state the sex of the animals
- 24% reported neither age nor weight of animals
- 4% did not mention the number of animals used
- 35% which reported numbers used these differed in the materials and methods and the results sections
- etc.

A crisis in pre-clinical biomedical research

PERSPECTIVE

2012

doi:10.1038/nature11556

A call for transparent reporting to optimize the predictive value of preclinical research

Story C. Landis¹, Susan G. Amara², Faris Asadullah³, Chris P. Austin⁴, Robi Blumenstein⁵, Eileen W. Bradley⁶, Ronald G. Crystal⁷, Robert B. Darnell⁸, Robert J. Ferraiuolo⁹, John L. Goudreau¹⁰, John Huguenard¹¹, Katrina Kelner¹², Malcolm R. Macleod²³, John M. McEwen¹³, John D. Porter¹, Oswald Steward²⁴

PERSPECTIVE

The Economics of Reproducibility in Preclinical Research

Ben Goldacre
Bad Pharma: how
companies mislead
doctors and harm patients

Leonard P. Freedman^{1*}, Iain M. Cockburn²

2015

Design, power, and interpretation of studies in the standard murine model of ALS

SEAN SCOTT¹, JANICE E. KRANZ¹, JEFF COLE¹, JOHN M. LINCUM¹, KENNETH THOMPSON¹, NANCY KELLY¹, ALAN BOSTROM², JILL THEODOSS¹, BASHAR M. AL-NAKHALA¹, FERNANDO G. VIEIRA¹, JEYANTHI RAMASUBBU¹ & JAMES A. HEYWOOD¹

¹ALS Therapy Development Institute, Cambridge, Massachusetts, and ²Department of Epidemiology and Biostatistics, University of California, San Francisco, USA

nature
genetics

EDITORIAL

2012

The '3Is' of animal experimentation

Animal experimentation in scientific research is a good thing: important, increasing and often irreplaceable. Careful experimental design and reporting are at least as important as attention to welfare in ensuring that the knowledge we gain justifies using live animals as experimental tools.



ELSEVIER

2012

Contents lists available at SciVerse ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox

Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize

Robin Mesnage^a, Steeve Gress^a, Nicolas Defarge^a, Joël Spiroux de Vendômois^a,
^aUMR1065, MRSN-CNRS, EA 2608, Esplanade de la Paix, Caen Cedex 14032, France
^bDepartment of Food Safety and Food Quality, University of Turin, 10125, Italy
^cDepartment of Biological, Morphological and Motor Sciences, Verona 37134, Italy

Raise standards for preclinical cancer research

C. Glenn Begley and Lee M. Ellis propose how methods, publications and incentives must change if patients are to benefit.

2010

Believe it or not: how much can we rely on published data on potential drug targets?

Florian Prinz, Thomas Schlange and Khusru Asadullah

2012


SOD1^{G93A}: The standard model for FALS and ALS



Scott et al (2008) Amyotrophic Lateral Sclerosis 9:4-15

- >50 papers describing therapeutic agents which extend lifespan in mice
- Only one (riluzole) has any clinical effect
- Scott et al:
 - Confounding factors (gender, litter, censoring, copy number) identified & controlled.
 - Power analysis used to determine an appropriate sample size
 - 70 compounds subsequently tested. None (including riluzole) increased survival.
- “The majority of published effects are most likely measurements of noise in the distribution of survival means as opposed to actual drug effects.”

Cost of irreproducible pre-clinical research in the USA alone



US\$28,000,000,000 per annum (US\$28 billion)




Fig 1. Studies reporting the prevalence of irreproducibility. Source: Begley and Ellis [6], Prinz et al. [7], Vasilevsky [8], Hartshorne and Schachner [5], and Glasziou et al. [9].

doi:10.1371/journal.pbio.1002165.g001

Some possible causes of lack of repeatability (false positives)



- Bias: incorrect or no randomisation/blinding (Due to use of the “Completely randomized” experimental design).
- Pseudo-replication: failure to identify the experimental unit correctly with over-estimation of “n” (e.g. animals/cage)
- Wrong animals (large species/strain differences in mice and rats)
- Failure to repeat or build in repetition (e.g. using randomised block designs). (*In-vitro* experiments “repeat the experiment 3 times”)
- Under-powered. Negative results remain unpublished. Excessive false positives due to the 5% significance level
- Technical errors. E.g. wrong monoclonal Abs.
- Statistical errors. E.g. assumptions invalid when doing parametric tests
- Fraud

Clear evidence of conflicts of interest impacting results



Positive results in studies of endocrine disruption by bisphenol A.

94/104 = 90% Government funded
0/11 = 0% Industry funded

Frederick S. vom Saal and Claude Hughes.
Environ Health Perspect 113:926–933 (2005)

The father of the randomised, controlled experiment



Sir Ronald Aylmer Fisher FRS (1890 – 1962), who published as R. A. Fisher, was an English statistician, and biologist, who used mathematics to combine Mendelian genetics and natural selection,... [wikipedia.org](https://en.wikipedia.org)


“To consult the statistician after an experiment is finished is often merely to ask him to conduct a post mortem examination. He can perhaps say what the experiment died of.”

The randomised controlled experiment: basic principles




Developed at the Rothamsted Experimental Station in the 1920s, largely by RA Fisher.

1. Replication



Sample size = 3

2. Randomization



A "completely randomized design"

3. Blocking



A Randomized block design


Basic designs: Completely randomised and randomised block experiments

First in theory, then real examples



A completely randomised design

There can be any number of treatments (3 here). "Treatment" is a *fixed effect factor*




This has one fixed effect factor "treatment" (three treatments)

Statistical analysis is a one-way ANOVA

ANOVA					
Source	DF	SS	MS	F	P
Treatment	2				
Error	9				
Total	11				

A randomised block design




Each block is randomised separately. It has two factors "Treatment" (fixed effect) and "Block" (random effect).

The statistical analysis is a 2-way ANOVA without interaction.

Source	DF
Blocks	3
Treatment	2
Error	6
Total	11

Each block has a single subject on each treatment.
Blocks can be separated in space and time.
Animals within a block should be matched



The research environment

“Our lives and the lives of animals are governed by cycles,
Seasons,
reproductive cycle, weekend-working days,
cage change/room sanitation cycle,
and the diurnal rhythm.

Some of these may be attributable to routine husbandry,
the rest are cycles, which may be affected by husbandry procedures.

Other issues to be considered are
in-house transport,
Environmental effects of cage location,
The physical environment inside the cage (wet/dry),
The acoustic environment audible to animals,
The olfactory environment, materials in the cage, cage complexity, feeding
regimens, kinship and interaction with humans.”

Barometric pressure
Lunar cycle?

*Nevalainen T. Animal husbandry and experimental design. ILAR J
2014;55(3):392-8.*

The randomized block design



- More powerful (better control of the research environment)
- More convenient.
 - Work spread over time
- Less subject to bias
 - Separate randomizations for each block
 - Discourages use of historical controls or adding on of additional treatment groups post-hoc
- Makes good use of heterogeneous material
 - Animals within a block matched

Factorial designs



(By using a factorial design)“.... an experimental investigation, at the same time as it is made more comprehensive, may also be made more efficient if by more efficient we mean that more knowledge and a higher degree of precision are obtainable by the same number of observations.”


R.A. Fisher, 1960

“..we should, in designing the experiment, artificially vary conditions if we can do so without inflating the error.

Cox, DR 1958



Basic designs: Completely randomised and randomised block 2x4 factorial experiments




2 genders (tall/short) x 4 treatments (black, blue, brown, red)

A completely randomised “Factorial” design with four treatments and two “genders, (male tall) and females (short), all fixed effects

ANOVA 2-way with interaction

Source	DF
Treatment (T)	3
Gender (G)	1
TxG	3
Error	8
Total	15



Block 1

Block 2

Each block has a single representative of each gender and treatment

A 4 (treatments)x2 (genders) factorial design (fixed effects) in two blocks (random effects). Analysis 3-way ANOVA with two fixed and one random factor (the blocks).

Source	DF
Blocks	1
Treatments	3
Gender	1
TxG	3
Error	7
Total	15

Randomisation, the p-value and the significance level: the basis of statistical testing (RA Fisher and the tea tasting experiment)



A lady claims that she can tell whether the milk is put in the cup before or after the tea. An experiment is set up to test this. Eight cups of tea are prepared, with four TM and four MT. They will be presented to the lady in random order and she will indicate which type they are.



Number of ways of choosing four cups out of eight cups =

$$\frac{n!}{r!(n-r)!} = 1680/24 = 70. \text{ Only } 1/70 \text{ is right, so if she does it correctly } p=0.014$$

A 5% significance level is often chosen for making a decision to accept the results as not due to chance, but this is entirely arbitrary.

P-value. Probability of getting a result as extreme as, or more extreme than the observed one in the absence of a true effect

NHST (null hypothesis significance testing) has some critics



Recently the editors of [*Basic and Applied Social Psychology*](#) (*BASP*) announced that the journal would no longer publish papers containing P values because the statistics were too often used to support lower-quality research.


Original Articles

Life After NHST: How to Describe Your Data Without “ p -ing” Everywhere

[Jeffrey C. Valentine](#), [Ariel M. Aloe](#) & [Timothy S. Lau](#)


Pages 260-273 | Published online: 04 Aug 2015

The “standardised effect size”, SES, or Cohen’s *d*



A measure of the magnitude of a difference between means **in units of standard deviations**. A partial replacement of NHST?

$$d = ES / SD_p \quad \text{Effect size} = \text{response in standard deviation units}$$




Example: Mean treated=3.30, mean control =1.55 , diff= 1.75. SD= 0.89
 So $d = 1.75 / 0.89 = 1.96$ SDs




Use of SESs in describing results of toxicity tests. All results converted from original units to SESs.

All biomarkers, both sexes



All biomarkers, both sexes




Michael Festing

DOI: 10.1177/0192623313517771

Toxicol Pathol published online 31 January 2014

Highlight the most changed biomarkers of toxicity



Michael Festing

DOI: 10.1177/0192623313517771

Toxicol Pathol published online 31 January 2014

Use of SES to study toxicity of GM crops in rats




FIGURE 4. qq plot for the combined biomarkers for SES1 and SES2 (both comparing GM with non-GM) and SES5 and SES7 (comparing non-GM with non-GM), a total of 380 SESs (Mackenzie et al. 2007). A p value of .544 using the Shapiro Wilks test suggests that there is no evidence that the SESs deviate from a normal distribution, although

Michael Festing

DOI: 10.1177/0192623313517771

Toxicol Pathol published online 31
January 2014

This study has produced 380 differences between hematology, clinical biochemistry and organ weights in animals fed on GM corn and non GM corn. When plotted on a normal probability plot they are normally distributed. No evidence of toxicity.



Three types of experiment

- Pilot study
 - Logistics and preliminary information
- Exploratory experiment
 - Aim is to provide data to generate hypotheses
 - May “work” or “not work”
 - Often many outcomes
 - Statistical analysis may be problematical (many characters measured, data snooping). p-values may not be correct
 - “The Texas sharp-shooter problem”
- Confirmatory experiment (Gold standard)
 - Formal hypothesis stated *a priori*. Randomised controlled experiment.
 - Various designs including “completely randomised” and “randomised block” designs.

A well designed confirmatory experiment



- Clearly stated objectives
 - Absence of bias
 - Experimental unit, randomisation, blinding
 - High power
 - Low noise (uniform material, blocking, covariance)
 - High signal (sensitive subjects, high dose)
 - Large sample size
 - Wide range of applicability
 - Replicate over other factors (e.g. sex, strain): factorial designs
 - Simplicity
 - Amenable to a statistical analysis
 - Planned with the design
- Internal validity
- External validity

Real Example 1.

A completely randomised (CR) design

Purpose of the study:

Do MCA and Urethane increase micronuclei in the peripheral blood of BALB/c female mice.

12 mice per group.

Treatments were assigned to mice at random.

Micronuclei were counted blind using the laser scanning cytometer.

Problems with a CR design:

1. May not be possible to obtain large numbers of animals of uniform weight, age etc.
2. May not be able to house them them in a uniform environment
3. May not be able to measure them in a uniform environment

So, inter-individual variability may be increased, and power decreased, because: SD increased.


However, the design is simple and is widely used.

Animal	Treatment	Count
1	Urethane	3.48
2	Control	1.9
3	Control	1.23
4	MCA	1.26
5	MCA	2.34
6	Urethane	5.39 *
7	Control	2.06
8	Urethane	2.34
9	MCA	1.55
10	MCA	2.26
11	Control	1.87
12	Control	0.66
13	Urethane	3.85
14	Urethane	1.57
15	MCA	2.00
16	Control	2.15
17	MCA	2.13
18	MCA	2.27
19	Urethane	3.56
20	MCA	1.98
21	MCA	1.76
22	Control	1.22
23	Urethane	6.10 *
24	Control	1.59
25	Control	1.88
26	Control	2.23
27	MCA	1.87
28	Control	0.33
29	Urethane	2.15
30	MCA	0.83
31	Urethane	2.81
32	Control	1.48
33	Urethane	2.9
34	MCA	0.75
35	Urethane	2.49
36	Urethane	3.04



Statistical analysis

Plot individual points



“jitter” added so points separated horizontally

ANOVA

assumptions:

1. Equal variances
2. Residuals have normal distribution
3. Independent experimental units.

What about the two outliers?

(do they make a difference to the conclusions?)


A trial ANOVA (to look at residuals)



Source	Df	SS	MS	F	P
Treatment	2	22.196	11.0982	13.997	<0.001
Residuals	33	26.165	0.7929		
Total	35	48.361			

Pooled sd= $\text{sqrt}(.7929) = 0.890$



Pooled variance



Residuals diagnostic plots



aov(Count ~ Treatment)



Assumptions for a parametric analysis:

1. Normal distribution of residuals
2. Homogeneous variances
3. Observations are independent (part of the design)

Should be a scattering of points with no pattern

Points should fall on a straight line

Means and standard deviations



Treat.	mean	sd	n	Post-hoc comparisons*
Control	1.55	0.596	12	a
MCA	1.75	0.546	12	a
Urethane	3.30	1.313	12	b

Pooled sd = 0.89 (from sqrt EMS in ANOVA)

*post-hoc comparisons done using Tukey's test

Standardised effect sizes/Cohen's d :

d (SES) = (Diff. between means)/pooled SD)

SES: MCA = $(1.75-1.55)/0.89 = 0.22$


Urethane = $(3.30-1.55)/0.89 = 1.96$

Note: I have been inconsistent & used SES and Cohen's d for the same thing

Example 2. A randomised block experiment



Do “CPG and STAU increase apoptosis in rat thymocytes?
Experimental unit is a dish of thymocytes



Advantages of randomised block designs



- If blocked in time, provides some assurance of repeatability
 - In-vitro experiments often say “We repeated the experiment three times”
- More powerful than CR design. Better control of variation.
Two animals treated at same time and housed in adjacent cages likely to be more similar than two treated at different times and housed on different shelves.
- More convenient: can be done a bit at a time
- Less susceptible to faulty randomisation

- Disadvantages:
- Not so good with several missing observations /unequal sample sizes (a few tolerated)
- Requires a 2-way ANOVA without interaction



ANOVA (MINITAB)

```
Week      random      3  1, 2, 3
Drug      fixed        3  C, CGP, STAU
```

Analysis of Variance for apop


Source	DF	SS	MS	F	P
Week	2	21764.2	10882.1	114.82	0.000
Drug	2	2129.6	1064.8	11.23	0.023
Error	4	379.1	94.8		
Total	8	24272.9			



An estimate of the
pooled variance

S = 9.73539 R-Sq = 98.44%


Residuals plots (done with MINITAB)





Means etc

Group Mean
C 365
CPG 383
STAU 403*
Pooled SD= 9.7



Post-hoc comparison:
Dunnett Simultaneous Tests
Response Variable apop
Comparisons with Control Level
treat = C subtracted from:

	Difference of Means	SE of Difference	Adjusted T-Value	P-Value
CPG	18.00	7.949	2.264	0.1419
STAU	37.67	7.949	4.739	0.0155

Standardised effect sizes
CPG = $(383-365)/9.7 = 1.85$
STAU = $(403-365)/9.7 = 3.91$

Example 3

Factorial designs



(By using a factorial design)“.... an experimental investigation, at the same time as it is made more comprehensive, may also be made more efficient if by more efficient we mean that more knowledge and a higher degree of precision are obtainable by the same number of observations.”

R.A. Fisher, 1960

“..we should, in designing the experiment, artificially vary conditions if we can do so without inflating the error.

Cox, DR 1958

Example 3. Factorial designs are widely used but often incorrectly analysed



Number of studies 513 (Neuroscience papers)
Factorial designs 153 (30%)
Correctly analysed 78 (50%)

Nieuwenhuis et al (2011) Nature Neurosci. 14:1105


Need a 2-way ANOVA **with interaction**

Example 3. Factorial “designs”

(they are really an arrangement of treatments)




Factorial design




$$E=16-4 = 12$$

Single factor design



$$E=16-2 = 14$$

One variable at a time (OVAT)



$$E=16-2 = 14$$

$$E=16-2 = 14$$

Example 3a. Effect of chloramphenicol on RBC counts (2000 μ g/kg)




No interaction

	Strain	Control	Treated	Strain means
Want to know:	BALB/c	10.10	8.95	
		10.08	8.45	
	1. Does treatment have an effect on RBC counts	9.73	8.68	
		10.09	8.89	9.37
	2. Do strains differ in RBC counts	C57BL	9.60	8.82
		9.56	8.24	
3. Do strains differ in their response (interaction)		9.14	8.18	
		9.20	8.10	8.86
	Treat.			
	Mean	9.69	8.54	



Example 3a. No interaction





Example 3a. No interaction

Analysis of Variance Table


Response: RBCs

	Df	Sum Sq	Mean Sq	F value	Pr(>F)	
Treatment	1	1.0661	1.0661	17.1512	0.001367	**
Strain	1	5.2785	5.2785	84.9232	8.595e-07	***
Treatment:Strain	1	0.0473	0.0473	0.7611	0.400108	
Residuals	12	0.7459	0.0622			

Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1
' ' 1

>


Example 3b. Effect of chloramphenicol (2000mg/kg) on RBC count



Significant Interaction

Strain	Control	Treated	Strain means
C3H	7.85	7.81	7.80
	8.77	7.21	
	8.48	6.96	
	8.22	7.10	
CD-1	9.01	9.18	8.58
	7.76	8.31	
	8.42	8.47	
	8.83	8.67	
Treatment means	8.42	7.96	

Example 3b. Interaction



Example 3b

ANOVA with significant interaction



Analysis of Variance Table

Response: RBCs

	Df	Sum Sq	Mean Sq	F value	Pr(>F)	
Strain	1	0.82356	0.82356	4.4302	0.057057	.
Treatment	1	2.44141	2.44141	13.1330	0.003489	**
Strain:Treatment	1	1.47016	1.47016	7.9084	0.015686	*
Residuals	12	2.23077	0.18590			


Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
>



Example 4. A 2x4 factorial design in two blocks.

Effect of diallyl sulphide (DS) on the activity of liver Gst in mice of four inbred strains

DS Administered by gavage in three daily doses of 0.2mg/g. to eight week old female mice



One female mouse per cage. The two blocks were separated by approximately 2 months



Example 4. A 2x4 factorial design in two blocks. Raw data

Table 1. Gst levels* from a RB experiment in two blocks separated by approximately three months.

Strain	Treatment	Block1	Block2
NIH	C	444	764
NIH	T	614	831
BALB/c	C	423	586
BALB/c	T	625	782
A/J	C	408	609
A/J	T	856	1002
129/Ola	C	447	606
129/Ola	T	719	766

* nmol conjugate formed per minute per mg of protein

Example 4.

Analysis of the results



ANOVA Gst activity Score

Source	Df	Sum Sq	Mean Sq	F value	Pr(>F)
Block	1	124256	124256	42.0175	0.0003398
Strain	3	28613	9538	3.2252	0.0914353 .
Treatment	1	227529	227529	76.9394	5.041e-05 *
Strain:Treatment	3	49590	16530	5.5897	0.0283197 *
Residuals	7	20701	2957		

Treatment means

mean	data:n
C 535	8
T 774	8

Pooled SD = $\sqrt{2957} = 54.3$


Strain means

Strain	mean	n
129/Ola	634	4
A/J	718	4
BALB/c	604	4
NIH	663	4
Pooled SD	54.3	

SES(treatment) = $(774-535)/54.3=4.40$



Example 4. Mean responses in control and Diallyl Sulphide-treated animals



Error bars are least significant differences. If they overlap there is no significant difference ($p > 0.05$), if they do not, then there is a significant difference ($p < 0.05$)

A well designed experiment.

(Will have a formal design)




- Clearly stated objectives
 - Absence of bias
 - **Experimental unit, randomisation, blinding**
 - High power
 - Low noise (uniform material, blocking, covariance)
 - High signal (sensitive subjects, high dose)
 - Large sample size
 - Wide range of applicability
 - Replicate over other factors (e.g. sex, strain): factorial designs
 - Simplicity
 - Amenable to a statistical analysis
- Internal validity
- External validity




Experimental units (EUs)

A completely randomised design
Treatments assigned to individuals at
random.




N=6

EU: Smallest division of the experimental material such that any two EUs can receive different treatments



Experimental units (EUs)

Animals within cage/pen have same treatment. A completely randomised design




EU: A cage with two animals.



Experimental units (EU)

A randomised block design

Animal within pen have different treatments.



N=12

EU: Smallest division of the experimental material such that any two EUs can receive different treatments

Experimental units (EU)




A split plot design. What are the experimental units?


Animals within pen have different treatments.

For a split-plot analysis consult a statistician

Males




Females



EU: Smallest division of the experimental material such that any two EUs can receive different treatments


A “Crossover” (Randomised block) design (some authors also call this a repeated measures design)



EU: an animal for a period of time:

N=12

Teratology: mother treated, young measured



Mother is the experimental unit.

EU learning outcome 4.

Identify the experimental unit and recognise issues of non-independence (pseudo- replication).



What is the experimental unit

An investigator wants to see whether outbred stocks are more variable than inbred strains in a test involving insect antigens.

He bought 16 BALB/c mice and compare them with 16 ICR mice looking at within-group variation in 10 different immunological tests.

He found no difference in variability between the two groups.

He concluded that investigators could save a lot of money by using outbred stocks rather than inbred strains


What is the experimental unit?

Other comments?


Experimental unit is the strain and there is only one of each.

Need large sample sizes to test whether two groups differ in variability

Regression and correlation



Prediction of Y from X



Association between Variables A and B

Statistical analysis should fit the purpose of the study



A Completely Randomised Design Experimental unit??

Lesion diameter following microwave treatment of liver of pigs.

Power
(watts)

										Mean	
50	3.3	3.2	2.8	2.8	2.4	2.7	3.2	3.8	1.5	2.9	
100	4.7	4.0	3.5	4.4	3.9	4.8	4.4	3.7	4.0	4.2	
150	5.5	5.0	4.4	4.5	6.0	6.5	5.0	5.0		5.3	
200	5.8	6.0								5.9	

Lesion diameter clearly increases with power, but aim is to quantify this


Regression analysis



Power and lesion diameter

$$\text{Diameter} = 1.8 + 0.022 \text{ power}$$

S = 0.61 R-Sq = 76 % R-Sq(adj) = 75 %






Randomisation

The animals are remarkably uniform. Why do we need to randomise them?

Why not assign alternatively to the two groups?

If we did this, what would be the experimental unit?



Randomisation and blinding using EXCEL



Animal

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12

Randomising a randomised block design

3 treatments, A, B, C.
4 blocks 1-4



Original unsorted			Sorted on rand()			2 nd . Sort on block			
Treatment	Block	RandomNo	Treatment	Block	RandomNo	Treatment	Block	RandomNo	ID
A	1	0.208	A	3	0.779				1
A	2	0.642	B	1	0.333				2
A	3	0.322	A	1	0.544				3
A	4	0.098	C	2	0.797				4
B	1	0.974	B	2	0.162				5
B	2	0.687	B	4	0.907				6
B	3	0.113	C	4	0.471				7
B	4	0.827	C	1	0.162				8
C	1	0.405	A	4	0.906				9
C	2	0.543	A	2	0.701				10
C	3	0.147	B	3	0.416				11
C	4	0.292	C	3	0.719				12

Each block blinded once
treatments have been given

Failure to randomise and/or blind leads to more “positive” results



Blind/not blind	odds ratio	3.4 (95% CI 1.7-6.9)
Random/not random	odds ratio	3.2 (95% CI 1.3-7.7)
Blind Random/ not blind random	odds ratio	5.2 (95% CI 2.0-13.5)

290 animal studies scored for blinding, randomisation and positive/negative outcome, as defined by authors

Bebarta et al 2003 Acad. emerg. med. 10:684-687

Classification variables



Some variables such as gender and genotype are “classifications” instead of being “treatments”.

Animals to be compared should be the same age and from the same environment and should be housed and measured in random order.

Inbred strains or outbred stocks



Isogenic strains (inbred, F1)

- Isogenic (animals identical)
- Homozygous, breed true (not F1)
- Phenotypically uniform
- Defined (quality control)
- Genetically stable
- Extensive background data with genetic profile
- Internationally distributed


Like immortal clones of genetically identical individuals. Several hundred strains available.

Outbred stocks

- Each individual different
- Do not breed true
- Phenotypically variable
- Not defined (no QC)
- Genetic drift can be rapid
- Validity of background data questionable. No genetic profile
- Not internationally distributed

Cheap and widely used, but the cost of the animals is a small proportion of total costs

22 Nobel prizes since 1960 where use of inbred strains was essential



Immunology

- Medawar and Burnet- Immunological tolerance (1960)
- Doherty and Zinkhanage-MHC restriction (1996)
- Beutler and Steinman-innate immunity (2011)
- Tonegawa-antibody diversity (1987)
- Jerne -T-cell receptor (1984)
- Snell-Transplantation loci (1980)
- Kohler and Milstein-monoclonal antibodies (1984)

Genetic modification

- Evans-embryonic stem cells (2007)
- Capecchi-homologous recombination (2007)
- Smithies-genetic modification (2007)

Genetics

- Axel and Buck-genes for olfaction (2004)

Transmissible encephalopathies

- Pruisiner (1997)

Growth factors

- Cohen, Levi-Montalcini (1986)

Cancer

- Varmus (1989), Bishop (1989), Baltimore (1975), Temin (1975)

Why do scientists continue to use outbred stocks when inbred strains are available?



Humans are outbred

We wish to model humans

Therefore we should use outbred animals

Why do scientists continue to use outbred stocks when inbred strains are available?




Humans weigh 70 kg
We wish to model humans

Therefore we should use 70 kg animals


What do we mean by “model” ?



Models and the high fidelity fallacy (after Russell and Burch)



The determination of sample size



Three methods of determining sample size

“Tradition”

Copy other investigators in the same discipline. Some merit, but ERCs & funders often want a power analysis.

Resource equation

Based on practical experience. Experiments should have between about 10 and 20 degrees of freedom in the analysis of variance of the results. But ERCs & funders often want a power analysis..

Power analysis

Makes use of the mathematical relationship between the six variables that can determine sample size when there are two treatments. Complex and widely misunderstood. It is not an objective method of determining sample size because it requires a subjective estimate of the minimum effect size likely to be of scientific interest. It also has “spurious precision”

Tradition



“Except in rare instances....., a decision on the size of the experiment is bound to be largely a matter of judgement and some of the more formal approaches to determining the size of the experiment have spurious precision”.

Cox DR, Reid N. The theory of the design of experiments.
Boca Raton, Florida: Chapman and Hall/CRC Press; 2000.


Sir David Cox has written two books on experimental design and is the first winner of the “International Statistics prize”. There are few other statisticians in the world who are as highly respected. He and Dr Reid are clearly referring to the power analysis when they mention “spurious precision”

Power Analysis for sample size and effects of variation





- A mathematical relationship between six variables. Fix five of these to determine the 6th one.
- Needs subjective estimate of effect size to be detected (signal)
- Has to be done separately for each character
- Not easy to apply to complex designs
- Essential for expensive, simple, large experiments (clinical trials)
- Useful for exploring effect of variability
- Not objective. It requires an estimate of size of treatment effect that the investigator wants to be able to detect

Factors affecting power and sample size



Standardised effect size (d) as a function of sample size for four levels of power



Assuming a 2-sided test.

Vertical lines correspond to sample sizes for the Resource Equation method.

A simplified way of determining sample size using a power analysis.



SES (Cohen's d) for 80% & 90% power one or two sided assuming a 5% significance level

Sample size	80% one sided	90% one sided	80% Two-sided	90% Two-sided
4	2.00	2.35	2.38	2.77
5	1.72	2.03	2.02	2.35
6	1.54	1.82	1.80	2.08
7	1.41	1.66	1.63	1.89
8	1.31	1.54	1.51	1.74
9	1.23	1.44	1.41	1.63
10	1.16	1.36	1.32	1.53
11	1.10	1.29	1.26	1.45
12	1.05	1.23	1.20	1.39
13	1.00	1.18	1.15	1.33
14	0.97	1.14	1.10	1.27
15	0.93	1.10	1.06	1.23
16	0.90	1.06	1.02	1.18
17	0.87	1.03	0.99	1.15
18	0.85	1.00	0.96	1.11
19	0.82	0.97	0.93	1.08
20	0.80	0.94	0.91	1.05
21	0.78	0.92	0.89	1.03
22	0.76	0.90	0.86	1.00
24	0.73	0.86	0.83	0.96
26	0.70	0.82	0.79	0.92
28	0.67	0.79	0.76	0.88
30	0.65	0.76	0.74	0.85
32	0.63	0.74	0.71	0.82
34	0.61	0.72	0.69	0.80

Suggested procedure

1. Find an SD for character of interest
2. Choose a sample size based on previous experience/published work, available resources
3. Look in table (left) to find Cohen's d for chosen power and sidedness
4. Multiply d by the SD to get effect size (ES: difference between means) in original units
5. Decide whether this ES is sufficient. e.g.. would it be better to be able to find a smaller ES? If so, choose a larger sample size and repeat.
6. Explain any calculations and assumptions in manuscript

Estimating sample/effect size for an experiment



Question: **Does your new drug alter RBC count in mice?**

Sample Size	d or SES 90% 2 sided
4	2.77
5	2.35
6	2.08
7	1.89
8	1.74
9	1.63
10	1.53
11	1.45
→ 12	1.39
13	1.33
14	1.27
15	1.23
16	1.18
17	1.15
18	1.11
19	1.08
20	1.05
21	1.03
22	1.00
24	0.96
26	0.92
28	0.88
30	0.85
32	0.82
34	0.80

1. From literature C57BL /6 mice have a mean Red Blood Cell count of 9.19, SD=0.40 (n/μL).

2. Say your preliminary choice is a sample size of n=12 mice/group

3. From table, left, for 90% power, two sided d=1.39

4. Detectable effect size=d*SD, = 1.39*0.40=0.56 n/μL

5. This is a $(0.56/9.19)*100= 6\%$ change.

6. Is this OK? If not, change sample size.

If you used 24 mice/group the predicted ES would be $0.96*0.40=0.38$ n/μL., a 4% change

7. You state: “From published work the mean and standard deviation of RBC in C57BL/6 mice is about 9.19 ± 0.40 . Using a power analysis I estimated that a sample size of n=12 will provide a 90% chance of detecting a change in RBC count of 0.56 n/μL or 6%.”

Cohen's d from previous examples



Example 1. Effect of MCA and urethane on micronuclei.

MCA, $d=0.22$ (ns)

Urethane $d=1.96$

Example 2. Apoptosis in rat thymocytes

CPG $d=1.85$ (ns)

STAU $d=3.91$

Example 3. Explaining factorial designs (see next slide)






Example 4. Randomised block factorial design, effect of diallyl sulphide

$d=4.4$

Other studies: Cohen's d is often well above 2.0 SDs in laboratory animal experiments.

So sample sizes can be small if variation controlled.

Examples of Cohen's d (SES) in chloramphenicol experiment.



$d=1$ “extra large”,
 $d=2$ “gigantic”

Note differences

due to

1. Strain
2. Dose
3. Character

Data from:

Festing MFW, Diamanti P, Turton JA. Strain differences in haematological response to chloramphenicol succinate in mice: implications for toxicological research. Food and Chemical Toxicology 2001;39:375-83.

The ARRIVE Guidelines.

Main headings



1. TITLE.

2. ABSTRACT

INTRODUCTION

3. Background.

➡ 4. Objectives.

METHODS

5. Ethical statement

➡ 6. Study design

7. Experimental procedures.

8. Experimental animals

9. Housing and husbandry

➡ 10. Sample size

➡ 11. Allocating animals to experimental groups

12. Experimental outcomes

➡ 13. Statistical methods

RESULTS

14. Baseline data

15. Numbers analysed

16. Outcomes and estimation

17. Adverse events

DISCUSSION

18. Interpretation/scientific implications

19. Generalisability/translation.

20 Funding

Kilkenny, C., W.J. Browne, I.C. Cuthill, M. Emerson, and D.G. Altman. 2010. "Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research." *PLoS Biol.* 8:e1000412.

Design of procedures and projects (level 1)

– EU Modules 10 and 11




1. Describe the concepts of fidelity and discrimination (e.g. as discussed by Russell and Burch and others).
2. Explain the concept of variability, its causes and methods of reducing it (uses and limitations of isogenic strains, outbred stocks, genetically modified strains, sourcing, stress and the value of habituation, clinical or sub-clinical infections, and basic biology).
3. Describe possible causes of bias and ways of alleviating it (e.g. formal randomisation, blind trials and possible actions when randomisation and blinding are not possible).
4. Identify the experimental unit and recognise issues of non-independence (pseudo- replication).
5. Describe the variables affecting significance, including the meaning of statistical power and “p-values”.
6. Identify formal ways of determining of sample size (power analysis or the resource equation method).
7. List the different types of formal experimental designs (e.g. completely randomised, randomised block, repeated measures [within subject], Latin square and factorial experimental designs).
8. Explain how to access expert help in the design of an experiment and the interpretation of experimental results

Design of procedures and projects (level 2)


– EU Modules 9, 10, 11 Good scientific practice



1. Describe the principles of a good scientific strategy that are necessary to achieve robust results, including the need for definition of clear and unambiguous hypotheses, good experimental design, experimental measures and analysis of results. Provide examples of the consequences of failing to implement sound scientific strategy
2. Demonstrate an understanding of the need to take expert advice and use appropriate statistical methods, recognise causes of biological variability, and ensure consistency between experiments.
3. Discuss the importance of being able to justify on both scientific and ethical grounds, the decision to use living animals, including the choice of models, their origins, estimated numbers and life stages. Describe the scientific, ethical and welfare factors influencing the choice of an appropriate animal or non-animal model.
4. Describe situations when pilot experiments may be necessary.
5. Explain the need to be up to date with developments in laboratory animal science and technology so as to ensure good science and animal welfare
6. Explain the importance of rigorous scientific technique and the requirements of assured quality standards such as GLP.
7. Explain the importance of dissemination of the study results irrespective of the outcome and describe the key issues to be reported when using live animals in research e.g. ARRIVE guidelines.




2002



2016

<https://uk.sagepub.com/en-gb/eur/the-design-of-animal-experiments/book252408>

ISBN: 9781473974630 £15.99




WWW. 3Rs- Reduction.co.uk

This site provides an interactive short course on experimental design for research scientists working with laboratory animals. The aim is to reduce the number of animals which are used, improve the quality of the science and save time, money and other scientific resources. Ethical review committees, IACUCs and Ph.D. supervisors might like to ask scientists starting work with animals to visit the site, work through it sequentially, and certify (using the form provided) that they have done so before starting their experiments.



© Michael FW Festing. No part of this web site may be used for commercial purposes

[Enter site](#)



14. Guidelines, systematic reviews and meta analysis

Guidelines

Click arrow for a pdf of "Guidelines for "The Design and Statistical Analysis of Experiments Using Laboratory Animals"



Important information which is essential should the work need to be repeated, or if it is to be included in a systematic review or meta-analysis is often omitted.

The "ARRIVE" guidelines and GSPC (Gold standard Publication Checklist), which overlap to a large extent, provide checklists of information which the authors should consider **when designing their experiment and preparing their manuscript**. Not all the items will be relevant to every paper, but all should be considered.

Main table from
The ARRIVE guidelines

Or click arrow for a pdf of the paper



Main table from
The GSPC

Or click arrow for a pdf of the paper





Conclusions

- We are not born knowing how to design a randomised controlled experiment. We need to be taught how to do so.
- Clearly, animal experiments are not always well designed
- Five requirements for a good design
 - Unbiased (randomisation, blinding, randomized block design)
 - Powerful (control variability, uniform materials, blocking)
 - Wide range of applicability, e.g. using factorial designs
 - Simple
 - Amenable to statistical analysis
- Use a power analysis to estimate effect size for a proposed sample size
- Use a randomized block design where possible
- Better training is needed (how?)
- More consultant bio-statisticians should be provided (free?)
- Funding organisations should take responsibility for the quality of the research that they fund!
- Negative results should be as acceptable as positive ones.